Warpaint London (LON:W7L) Reaches New 52-Week Low - Time to Sell?

Key Points

• Warpaint London PLC shares hit a new 52-week low, trading as low as GBX 305 ($4.12) and last at GBX 312 ($4.21), representing a decline from the previous close of GBX 317 ($4.28).
• Despite recent stock performance, Shore Capital maintains a "house stock" rating for Warpaint London, which has a consensus "Buy" rating and a target price of GBX 680.
• The company operates in the color cosmetics sector under various brand names and has a market capitalization of £247.28 million with a P/E ratio of 13.83.

Shares of Warpaint London PLC (LON:W7L - Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 305 ($4.12) and last traded at GBX 312 ($4.21), with a volume of 495457 shares traded. The stock had previously closed at GBX 317 ($4.28).

Analyst Ratings Changes

Separately, Shore Capital reaffirmed a "house stock" rating on shares of Warpaint London in a research note on Tuesday, June 17th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of GBX 680.

Warpaint London Trading Down 1.6%

The stock's fifty day moving average price is GBX 401.82 and its 200 day moving average price is GBX 401.81. The company has a debt-to-equity ratio of 2.55, a current ratio of 3.46 and a quick ratio of 1.56. The stock has a market capitalization of £247.28 million, a P/E ratio of 13.83 and a beta of 0.60.

Warpaint London Company Profile

Warpaint London PLC, together with its subsidiaries, provides color cosmetics. It operates through two segments, Branded and Close-Out. The company offers its cosmetic skincare products under the W7, Technic, Man'stuff, Body Collection, Very Vegan, and Chit Chat brand names. It also provides supply chain management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.